40 completed, 18 terminated, 1 withdrawn. 30 Phase 2, 26 Phase 1, 3 Not applicable, 3 Phase 3, 1 Early Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 30 | Completed 20, Terminated 9, Withdrawn 1 |
| Phase 1 | 26 | Completed 17, Terminated 9 |
| Not applicable | 3 | Completed 2, Terminated 1 |
| Phase 3 | 3 | Completed 3 |
| Early Phase 1 | 1 | Completed 1 |
Follow Adult Pure Erythroid Leukemia (M6b): new trials by email Literature Review of Adult Pure Erythroid Leukemia (M6b) trials Research Report on Adult Pure Erythroid Leukemia (M6b)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| Metformin+Cytarabine for the Treatment of Relapsed/Refractory AML metformin hydrochloride, cytarabine, laboratory biomarker analysis - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 1 | Terminated | Northwestern University | 2 | 2015-03-11 | 2019-01-31 |
| MEK Inhibitor MEK162, Idarubicin, and Cytarabine in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia MEK inhibitor MEK162, idarubicin, cytarabine - Adult Acute Minimally Differentiated Myeloid Leukemia (M0), Adult Acute Monoblastic Leukemia (M5a) | Phase 1 | Terminated | Bruno C. Medeiros | 1 | 2014-12-01 | 2017-12-06 |
| Eltrombopag Olamine in Improving Platelet Recovery in Older Patients With Acute Myeloid Leukemia Undergoing Chemotherapy eltrombopag olamine - Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Basophilic Leukemia | Phase 2 | Completed | Case Comprehensive Cancer Center | 31 | 2014-08-14 | 2026-08-07 |
| Omacetaxine Mepesuccinate, Cytarabine, and Decitabine in Treating Older Patients With Newly Diagnosed Acute Myeloid Leukemia cytarabine, omacetaxine mepesuccinate, decitabine - Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Megakaryoblastic Leukemia (M7) | Phase 2 | Terminated | Roswell Park Cancer Institute | 2 | 2014-07-01 | 2016-05-09 |
| Ixazomib (MLN9708) in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia Ixazomib - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 2 | Terminated | Steven E. Coutre | 4 | 2014-03-01 | 2019-04-05 |
| Lenalidomide and Combination Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia lenalidomide, mitoxantrone hydrochloride, etoposide - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 1 | Terminated | Stanford University | 17 | 2014-02-01 | 2018-10-29 |
| AML Therapy With Irradiated Allogeneic Cells fludarabine phosphate, cytarabine, donor lymphocytes - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Not applicable | Terminated | Rutgers, The State University of New Jersey | 6 | 2014-02-01 | 2021-08-24 |
| Treatment for Relapsed/Refractory AML Based on a High Throughput Drug Sensitivity Assay antitumor drug screening assay, chemotherapy, biological therapy - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Not applicable | Completed | University of Washington | 16 | 2013-08-02 | 2018-07-11 |
| Idarubicin, Cytarabine, and Pravastatin Sodium in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndromes pravastatin sodium, idarubicin, cytarabine - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Not applicable | Completed | Fred Hutchinson Cancer Center | 24 | 2013-05-01 | 2017-11-17 |
| Arsenic Trioxide in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia arsenic trioxide, laboratory biomarker analysis - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 2 | Withdrawn | Stanford University | 2013-05-01 | 2018-05-21 | |
| Lithium Carbonate and Tretinoin in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia tretinoin, lithium carbonate, laboratory biomarker analysis - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a) | Phase 1 | Completed | Paolo Caimi, MD | 12 | 2013-04-30 | 2017-04-27 |
| Sirolimus, Idarubicin, and Cytarabine in Treating Patients With Newly Diagnosed Acute Myeloid Leukemia Sirolimus, Idarubicin, Cytarabine - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a) | Early Phase 1 | Completed | Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University | 55 | 2013-03-15 | 2025-04-29 |
| Donor Stem Cell Transplant in Treating Patients With High Risk Acute Myeloid Leukemia mitoxantrone hydrochloride, cytarabine, peripheral blood stem cell transplantation - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a) | Phase 1 | Terminated | University of Southern California | 10 | 2013-03-06 | 2018-03-30 |
| Decitabine Followed by Idarubicin and Cytarabine in Treating Patients With Relapsed or Refractory AML and MDS decitabine, idarubicin, cytarabine - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a) | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 7 | 2012-07-01 | 2017-03-31 |
| Azacitidine, Cytarabine, and Mitoxantrone Hydrochloride in Treating Patients With High-Risk Acute Myeloid Leukemia azacitidine, cytarabine, mitoxantrone hydrochloride - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a) | Phase 1 | Completed | University of Chicago | 50 | 2012-06-06 | 2020-05-15 |
| Eltrombopag Olamine in Treating Patients With Relapsed/Refractory Acute Myeloid Leukemia eltrombopag olamine, standard follow-up care - Adult Acute Basophilic Leukemia, Adult Acute Eosinophilic Leukemia | Phase 1 | Terminated | Roswell Park Cancer Institute | 10 | 2012-05-01 | 2022-07-22 |
| Cholecalciferol in Treating Patients With Acute Myeloid Leukemia Undergoing Intensive Induction Chemotherapy cholecalciferol, pharmacological study, laboratory biomarker analysis - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Monoblastic Leukemia (M5a) | Phase 2 | Terminated | Roswell Park Cancer Institute | 4 | 2011-12-01 | 2015-06-19 |
| Bortezomib in Treating Patients With High-Risk Acute Myeloid Leukemia in Remission bortezomib - Acute Myeloid Leukemia With Multilineage Dysplasia Following Myelodysplastic Syndrome, Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 2 | Terminated | Fred Hutchinson Cancer Center | 6 | 2011-11-01 | 2017-04-04 |
| Trebananib With or Without Low-Dose Cytarabine in Treating Patients With Acute Myeloid Leukemia trebananib, cytarabine, laboratory biomarker analysis - Adult Acute Megakaryoblastic Leukemia (M7), Adult Acute Minimally Differentiated Myeloid Leukemia (M0) | Phase 1 | Completed | Roswell Park Cancer Institute | 24 | 2011-10-31 | 2022-09-13 |
| Cyclophosphamide for Prevention of Graft-Versus-Host Disease After Allogeneic Peripheral Blood Stem Cell Transplantation in Patients With Hematological Malignancies cyclophosphamide, cyclosporine, peripheral blood stem cell transplantation - Accelerated Phase Chronic Myelogenous Leukemia, Adult Acute Lymphoblastic Leukemia in Remission | Phase 2 | Completed | Fred Hutchinson Cancer Center | 43 | 2011-09-01 | 2017-05-19 |
Showing 20 of 59. Sign in to see all of them.
Leukemia, Erythroblastic, Acute (59) · Leukemia, Myeloid, Acute (59) · Congenital Abnormalities (58) · Leukemia, Monocytic, Acute (57) · Leukemia, Megakaryoblastic, Acute (56) · Leukemia, Myelomonocytic, Acute (55) · Leukemia, Basophilic, Acute (17) · Leukemia, Eosinophilic, Acute (17) · Precursor Cell Lymphoblastic Leukemia-Lymphoma (13) · Blast Crisis (10) · Leukemia, Myelomonocytic, Chronic (9) · Anemia, Refractory, with Excess of Blasts (7) · Leukemia, Promyelocytic, Acute (6) · Leukemia, Lymphocytic, Chronic, B-Cell (5) · Leukemia, Myeloid, Accelerated Phase (5)
Bone Marrow Diseases (59) · Hematologic Diseases (59) · Hemic and Lymphatic Diseases (59) · Leukemia (59) · Leukemia, Myeloid (59) · Neoplasms by Histologic Type (59) · Congenital, Hereditary, and Neonatal Diseases and Abnormalities (58) · Neoplasms (58) · Myeloproliferative Disorders (54) · Chronic Disease (16) · Disease Attributes (16) · Pathologic Processes (16) · Pathological Conditions, Signs and Symptoms (16) · Immune System Diseases (13) · Immunoproliferative Disorders (13)
Cytarabine (27) · Mitoxantrone (10) · Etoposide (9) · Idarubicin (7) · alvocidib (6) · tipifarnib (6) · Cyclosporine (5) · Daunorubicin (5) · Bortezomib (4) · Busulfan (4) · Peripheral Blood Stem Cell Transplantation (4) · Cyclophosphamide (3) · Decitabine (3) · Filgrastim (3) · Granulocyte Colony-Stimulating Factor (3)
National Cancer Institute (NCI) (29) · Fred Hutchinson Cancer Center (8) · Case Comprehensive Cancer Center (4) · Roswell Park Cancer Institute (4) · Rutgers, The State University of New Jersey (2) · Stanford University (2) · Bruno C. Medeiros (1) · ECOG-ACRIN Cancer Research Group (1) · Nohla Therapeutics, Inc. (1) · Northwestern University (1) · Paolo Caimi, MD (1) · Sidney Kimmel Comprehensive Cancer Center at Thomas Jefferson University (1) · Steven E. Coutre (1) · University of Chicago (1) · University of Southern California (1)
United States (58) · Israel (2) · India (1)
Judith Karp (6) · Roland Walter (4) · B. Smith (3) · Bruno de Medeiros (3) · Srdan Verstovsek (2) · Alex Adjei (1) · Anjali Advani (1) · Ann Mohrbacher (1) · Brenda Cooper (1) · Brenda Cooper, MD (1) · Brenda Sandmaier (1) · Colleen Delaney (1) · David Iberri (1) · Derek Stirewalt (1) · Douglas Ross (1)
PMID 31375516, PMID 36184192, PMID 19109557, PMID 20460644, PMID 20522709, PMID 21239698, PMID 21551228, PMID 21791475, PMID 22001391, PMID 22133771, PMID 22733022, PMID 23256542, PMID 23443507, PMID 23996484, PMID 24142996, PMID 24583795, PMID 26022709, PMID 26764356, PMID 26819054, PMID 27374466, PMID 32074275, PMID 32211336, PMID 32499241, PMID 34162404, PMID 41890705
U01CA070095 (10), P30CA015704 (5), P30CA006973 (4), N01CM62204 (3), U10CA031946 (3), N01CM62202 (2), P30CA072720 (2), P30CA124435 (2), U01CA062505 (2), U01CA076576 (2), U10CA021115 (2), U10CA032102 (2), N01CM00039 (1), N01CM00100 (1), P30CA014236 (1)